TY - JOUR
T1 - Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer
AU - Saeki, Hiroshi
AU - Kawaguchi, Hidetoshi
AU - Kitamura, Kaoru
AU - Ohno, Shinji
AU - Sugimachi, Keizo
PY - 1998/12/1
Y1 - 1998/12/1
N2 - Background and Objectives: Hyperthermochemoradiotherapy (HCR) has been performed on numerous patients with esophageal cancer. The purpose of this study is to demonstrate the recent advances in HCR. Methods: From 1965 to 1997, 294 patients given preoperative chemoradiotherapy (CR) or HCR were classified according to the anticancer agent that was administered (CR; group A given bleomycin (BLM); group B given cis-diamminedichloroplatinum (II) (CDDP), HCR; group C given BLM; and Group D given CDDP). The local response and the long-term results were investigated. Results: The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 79 (63.7%) in group C, and 36 (73.5%) in group D. A significant difference was observed between groups A and B (P < 0.05). The highest incidence of markedly effective cases was observed in group D. The 5- year survival rates for the group A and B patients were 17.2% and 43.9%, respectively (P < 0.01), while the same rates for those of groups C and D were 25.6% and 57.8%, respectively (P < 0.05). Our results thus showed CDDP to have a greater effect than BLM, while HCR had a greater effect than CR. Conclusions: Preoperative HCR has improved thanks to recent advances in anticancer agents.
AB - Background and Objectives: Hyperthermochemoradiotherapy (HCR) has been performed on numerous patients with esophageal cancer. The purpose of this study is to demonstrate the recent advances in HCR. Methods: From 1965 to 1997, 294 patients given preoperative chemoradiotherapy (CR) or HCR were classified according to the anticancer agent that was administered (CR; group A given bleomycin (BLM); group B given cis-diamminedichloroplatinum (II) (CDDP), HCR; group C given BLM; and Group D given CDDP). The local response and the long-term results were investigated. Results: The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 79 (63.7%) in group C, and 36 (73.5%) in group D. A significant difference was observed between groups A and B (P < 0.05). The highest incidence of markedly effective cases was observed in group D. The 5- year survival rates for the group A and B patients were 17.2% and 43.9%, respectively (P < 0.01), while the same rates for those of groups C and D were 25.6% and 57.8%, respectively (P < 0.05). Our results thus showed CDDP to have a greater effect than BLM, while HCR had a greater effect than CR. Conclusions: Preoperative HCR has improved thanks to recent advances in anticancer agents.
UR - http://www.scopus.com/inward/record.url?scp=0032438560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032438560&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1096-9098(199812)69:4<224::AID-JSO6>3.0.CO;2-I
DO - 10.1002/(SICI)1096-9098(199812)69:4<224::AID-JSO6>3.0.CO;2-I
M3 - Article
C2 - 9881939
AN - SCOPUS:0032438560
SN - 0022-4790
VL - 69
SP - 224
EP - 229
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 4
ER -
